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Introduction: The approved dual-color fluorescence in situ hybrid-
ization (FISH) test for the detection of anaplastic lymphoma receptor 
tyrosine kinase (ALK) gene rearrangements in non-small-cell lung 
cancer (NSCLC) is complex and represents a low-throughput assay 
difficult to use in daily diagnostic practice. We devised a sensitive 
and robust routine diagnostic test for the detection of rearrangements 
and transcriptional up-regulation of ALK.
Methods: We developed a quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) assay adapted to RNA isolated from routine 
formalin-fixed, paraffin-embedded material and applied it to 652 NSCLC 
specimens. The reliability of this technique to detect ALK dysregulation 
was shown by comparison with FISH and immunohistochemistry.
Results: qRT-PCR analysis detected unbalanced ALK expression 
indicative of a gene rearrangement in 24 (4.6%) and full-length 
ALK transcript expression in six (1.1%) of 523 interpretable tumors. 
Among 182 tumors simultaneously analyzed by FISH and qRT-PCR, 
the latter accurately typed 97% of 19 rearranged and 158 nonrear-
ranged tumors and identified ALK deregulation in two cases with 
insufficient FISH. Six tumors expressing full-length ALK transcripts 
did not show rearrangements of the gene. Immunohistochemistry 
detected ALK protein overexpression in tumors with gene fusions 
and transcriptional up-regulation, but did not distinguish between the 
two. One case with full-length ALK expression carried a heterozy-
gous point mutation (S1220Y) within the kinase domain potentially 
interfering with kinase activity and/or inhibitor binding.
Conclusions: Our qRT-PCR assay reliably identifies and distin-
guishes ALK rearrangements and full-length transcript expression in 
formalin-fixed, paraffin-embedded material. It is an easy-to-perform, 
cost-effective, and high-throughput tool for the diagnosis of ALK 
activation. The expression of full-length ALK transcripts may be rel-
evant for ALK inhibitor therapy in NSCLC.
Key Words: Non–small-cell lung cancer, Anaplastic lymphoma recep-
tor tyrosine kinase, Translocation and overexpression, Quantitative 
expression analysis, Routine diagnosis.
(J Thorac Oncol. 2014;9: 307–315)
Recently, considerable progress has been made in under-standing the molecular mechanisms of lung cancer patho-
genesis. This especially pertains to the development of novel 
treatment strategies. In particular, the identification of aber-
rantly activated tyrosine kinases (e.g., epidermal growth fac-
tor receptor [EGFR]) in subsets of non–small-cell lung cancer 
(NSCLC) together with the development of specific kinase 
inhibitors, has proven to be a successful approach to target 
individual tumors.
A subset of NSCLC harbors rearrangements of the ana-
plastic lymphoma receptor tyrosine kinase (ALK) gene, often 
with the echinoderm microtubule associated protein like 4 
(EML4) gene because of a small inversion within chromo-
some 2p,1,2 and more rarely with other fusion partners such as 
KIF5B3 and TFG.1 These rearrangements lead to the expres-
sion of a chimeric tyrosine kinase in which the ALK kinase 
domain is fused to the N-terminal part of the fusion partner. 
The tyrosine kinase inhibitor crizotinib has shown dramatic 
clinical responses in patients and transgenic mice with ALK-
rearranged tumors.4–6 The prevalence of ALK rearrangements, 
however, is low, ranging from 3% to 6% in adenocarcinomas.7,8 
Therefore, efficient patient selection may be a crucial issue in 
clinical practice. In the search for predictive characteristics, 
we found that parameters such as younger age, never/light 
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smoking history, and adenocarcinoma histology with signet-
ring cells were found to be associated with EML4-ALK gene 
fusions.9,10 However, fusion genes were also observed in older 
patients with smoking history.9 Therefore, selection of patients 
by clinical and structural characteristics is inappropriate, and 
molecular screening would clearly be desirable to identify the 
subset of ALK-positive tumors.
Currently, fluorescence in situ hybridization (FISH), 
reverse transcription polymerase chain reaction (RT-PCR) and 
immunohistochemistry (IHC) are used to detect ALK rear-
rangements.11 Although each method has its specific strengths, 
there is no perfect method for the detection of ALK gene altera-
tions especially in formalin-fixed, paraffin-embedded (FFPE) 
tissue samples in routine pathology practice. FISH is the gold 
standard technique that, however, requires specialized techni-
cal equipment and expertise and is a  low-throughput approach. 
Immunostaining of the ALK protein detects ALK rearrange-
ments reliably in cases with substantial protein expression; how-
ever, the interpretation of the result is often challenging because 
of a weak and variable immunoreactivity. RT-PCR amplifica-
tion of specific ALK fusion transcripts is very sensitive and can 
identify the fusion partner, but is rather complex because of the 
large number of fusion variants and cannot detect rearrange-
ments with hitherto unknown partners. Very recently, three 
assays were published that detect unbalanced ALK transcript 
expression. All three methods showed excellent sensitivity and 
specificity for the detection of ALK rearrangements, but are 
not adapted to poor-quality RNA characteristic of FFPE speci-
mens12 or are based on exon array or NanoString’s (Seattle, WA) 
nCounter technology, which is not available in most pathology 
laboratories.13,14 Therefore, those new approaches are difficult 
to exploit in daily diagnostic practice.
The aim of the present study, therefore, was to develop 
a robust diagnostic assay for the detection of ALK alterations 
in FFPE samples based on quantitative RT-PCR (qRT-PCR). 
This approach was applied to a large cohort of routine NSCLC 
specimens to determine (1) the reliability of the technique to 
detect ALK rearrangements in comparison with FISH and IHC 
and (2) the prevalence of transcriptional up-regulation of ALK 
in NSCLC.
MATERIALS AND METHODS
Specimen Collection
In this study we included FFPE tissue biopsies or resec-
tion specimens from 652 patients diagnosed with NSCLC 
that had been classified according to the World Health 
Organization classification for lung tumors.15 Basic medi-
cal records of the patients were reviewed to obtain clini-
cal information (age, sex, smoking status). The study was 
approved by the Ethics Committee of the University Hospital, 
 Eberhard-Karls-Universität Tübingen (Germany), and all 
sampling was performed according to respective protocols. 
FFPE samples from one anaplastic large-cell lymphoma, 
the NSCLC cell line H2228 (CRL-5935; ATCC, Rockville, 
MD), and the rhabdomyosarcoma cell line RH30 (DSMZ, 
Braunschweig, Germany) were used as positive controls for 
the expression of nucleophosmin (NPM)-ALK EML4-ALK, 
and full-length ALK transcripts, respectively.
RNA and DNA Preparation
Total RNA and genomic DNA were isolated from FFPE 
tissue samples by using the AllPrep DNA/RNA FFPE Kit as 
described by the manufacturer (Qiagen, Hilden, Germany). 
This extraction method was optimized by the manufacturer to 
reverse formaldehyde modification without further RNA deg-
radation and turned out to be the most efficient one for isolating 
nucleic acids of sufficient quality for PCR amplification when 
tested in our laboratory. Total RNA and genomic DNA were 
isolated from cell lines by using the AllPrep DNA/RNA Mini 
Kit (Qiagen) according to the manufacturer’s instructions.
Quantitative RT-PCR
Total RNA (1 μg for resection specimens, large biopsies, 
or control samples; 0.1–1 μg for small biopsies) was reverse 
transcribed using random hexamers and the SuperScript-First 
Strand Synthesis System for RT-PCR (Life Technologies, 
Darmstadt, Germany). Primers for qRT-PCR targeting the 
5´ and the 3´ portions of the ALK transcript (exons 4/5 and 
24/25) were designed based on published sequence data 
(NM_004304). As reference gene, phosphoglycerate kinase 1 
(PGK1) was used, which had been proven to represent a suit-
able internal control for normalizing NSCLC samples (data 
not shown). Primer sequences are shown in Supplementary 
Table 1 (Supplemental Digital Content 1, http://links.lww.
com/JTO/A511). qRT-PCR was carried out in an ABI PRISM 
7700 Sequence Detector by using the SYBR Green PCR kit 
(Life Technologies). Complementary DNA (50 ng for NSCLC 
samples, 10 ng for cell lines) was subjected to qRT-PCR reac-
tions containing 750 nM primer in a total volume of 25 μl. The 
cycling conditions were as follows: two initial incubations of 
2 minutes at 50°C and 10 minutes at 95°C, then 40 cycles of 
30 seconds at 95°C, and 1 minute at 60°C. Each sample was 
analyzed at least in duplicate (analysis was repeated in rare 
cases with discordant data). For data analysis, the threshold 
fluorescence was set at 0.045. NSCLC samples were excluded 
from the analysis if PGK1 amplification resulted in a fluo-
rescence threshold (Ct) value above 31. For ALK, we defined 
Ct=40 as our limit of detection, and Ct values beyond this 
limit were defined as negative and set to 40 for further cal-
culations. ALK expression was calculated by applying ∆∆Ct: 
For each sample, ALK expression was normalized to PGK1 
and calculated relative to the average value in cell line RH30, 
which was arbitrarily defined as 1. The cutoff value for altered 
ALK expression was 0.3 for both amplicons, corresponding 
to the mean value of ALK in 50 NSCLC cases with wild-type 
ALK (as confirmed by FISH) plus 3 SDs.
DNA Sequence Analysis
Direct sequencing of PCR products was performed 
by cycle sequencing with ABI PRISM BigDye Terminator 
chemistry followed by electrophoresis on an ABI-3100 auto-
mated sequencer (Life Technologies). ALK primer sequences 
are shown in Supplementary Table 1 (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A511). EGFR sequence 
analysis was performed as reported.16,17
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Fluorescence In Situ Hybridization
FISH was done on 4-μm thick FFPE tissue sections 
according to published protocols.18 Experiments were evalu-
ated using an epifluorescence microscope (Leica DMRA, 
Wetzlar, Germany). Images were captured using an Isis work-
station (Version 5.4; Metasystems, Altlussheim, Germany). 
ALK rearrangements were analyzed using a breakapart probe 
specific for the ALK locus (ZytoLight SPEC ALK/EML4 
TriCheckTM Probe; Zytomed Systems, Berlin, Germany). 
Signal evaluation was performed on at least 100 nuclei. Cases 
were regarded as FISH-positive if (1) separated green and 
orange signals (translocation) or (2) single orange signals 
(translocation and deletion of the ALK 5´ portion) were identi-
fied in at least 15% of tumor cells analyzed.
Immunohistochemistry
IHC was performed on 2-μm thick FFPE tissue sec-
tions using the Bond Automated Immunohistochemistry & 
In-Situ Hybridisation System (Menarini Diagnostics, Berlin, 
Germany). After heat-induced epitope retrieval with 1 mM 
EDTA (pH 9.0) rabbit monoclonal antihuman ALK antibody 
(1:100; D5F3; New England Biolabs, Frankfurt, Germany) 
was incubated for 30 minutes, followed by washing and detec-
tion according to the manufacturer’s protocol. ALK IHC was 
scored as follows: 0, no staining; 1+, faint or weak; 2+, mod-
erate; 3+, strong staining intensity in at least 10% tumor cells. 
IHC, FISH, and qRT-PCR evaluations were performed in a 
blinded fashion.
Statistical Analysis
For all calculations, Analyse-it software (Leeds, United 
Kingdom) for Microsoft Excel was used.
RESULTS
Establishment of the ALK qRT-PCR Assay
The ALK rearrangement leads to the overexpression 
of the 3´ portion of ALK encoding the kinase domain (exons 
20–29) whereas the 5´ portion (exons 1–19) remains unex-
pressed. On the basis of this we constructed a qRT-PCR assay 
consisting of two amplicons targeting the 5´ and the 3´ por-
tions of the ALK transcript separately (Fig. 1). Small amplicons 
FIGURE 1. ALK mRNA expression in NSCLC. A, Genomic structure of ALK according to NM_004304. Amplicons of the  qRT-PCR 
assay are indicated by boxes: red box, ALK 5' portion; blue box, ALK 3' portion. B, qRT-PCR analysis of ALK was performed relative 
to the PGK1 housekeeping gene and calculated relative to the average value in cell line RH30, which was arbitrarily defined as 
1. The horizontal dashed line indicates the cutoff value for altered ALK expression (0.3); red bars, ALK 5'portion; blue bars, ALK 3' 
portion. The asterisks point to tumors expressing full-length transcripts. ALK, anaplastic large-cell lymphoma kinase; NSCLC, non–
small-cell lung cancer; PGK1, phophoglycerokinase 1; qRT-PCR, quantitative reverse transcription polymerase chain reaction.
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(66–83 base pairs in size) were designed to overcome the tech-
nical problems associated with the use of fragmented FFPE 
RNA to arrive at efficient amplification and detection of ALK 
cDNA. Furthermore, we used an RNA isolation method that 
had been optimized by the manufacturer to reverse formalde-
hyde modification without further RNA degradation.
The amplification efficiency and theoretical sensitivity 
of the ALK qRT-PCT assay was validated by fourfold dilu-
tion series of RH30 cDNA in ddH
2
O (Supplementary Figure 1 
[Supplemental Digital Content 2, http://links.lww.com/JTO/
A512] shows representative standard curves). For both ampli-
cons the Ct values correlated with the ALK mRNA input 
over at least three orders of magnitude (linear regression: 
p = 0.0001).
The reliability of the ALK assay was assessed by study-
ing a series of FFPE samples with known ALK status as 
determined by FISH: one t(2;5) positive lymphoma and two 
NSCLC cases (#10, #17) with ALK translocations as well as 
10 NSCLC cases with wild-type ALK (#35 to #44). For the 
expression of EML4-ALK and full-length ALK transcripts, 
cell lines H2228 and RH30 were used as positive controls, 
respectively. Unbalanced ALK transcript expression was seen 
in all ALK translocated cases, all of them showing a signifi-
cant expression of the 3´ exons whereas the 5´ exons were not 
expressed. In all wild-type cases, neither 5´ nor 3´ exons were 
expressed (Fig. 1).
Screening for ALK Rearrangements by 
 qRT-PCR Assay and Correlation with FISH
To validate the ALK qRT-PCR assay in a larger series of 
FFPE diagnostic specimens, bronchoscopic biopsies or resec-
tion specimens (irrespective of size) from 652 NSCLC patients 
were screened for ALK rearrangements. In all cases, the tumor 
cell content was at least 10%. Five hundred  twenty-three cases 
(80%) were interpretable, that is, with RNA of sufficient qual-
ity obtained as indicated by efficient amplification of the con-
trol gene PGK1.
In 24 of 523 tumors (4.6%) an expression of the ALK 3´ 
portion with values above the cutoff level of 0.3 was observed 
(median value: 1.76, range, 0.32–7.10) whereas the 5´ por-
tion was not expressed (Table 1, Fig. 1B). Six tumors (1.1%) 
showed a significant expression of the full-length ALK tran-
script (Table 1, Fig. 1B). In those cases, the expression of 
the 3´ part ranged from 0.42 to 0.96 (median: 0.61) and of 
the 5´ part from 0.66 to 1.85 (median: 1.12). ALK was not 
expressed or at only very low levels (medium value: 0.05; 
range, 0.001–0.29) in 493 samples (94.3%; Fig. 1B).
To relate ALK expression to ALK gene rearrangements, 
198 samples were subjected to FISH analysis (tests performed 
in a blinded fashion). ALK breakapart FISH was interpretable 
in 92% (182 of 198) tumors and in 22 of the 24 tumors with 
unbalanced ALK expression. Of the latter, all 19 cases with 3´ 
expression values greater than 0.4 were confirmed to be ALK 
rearranged. Of note, in one case (# 8) FISH analysis revealed 
a translocation accompanied by a partial deletion of the 3´ 
part of ALK as indicated by separated green and very small 
orange signals. The critical question whether the crucial target 
region was still present in this case was answered by qRT-PCR 
demonstrating a significant expression of the 3´ ALK por-
tion (value 1.30). Three cases had expression levels between 
0.3 and 0.4 but showed a wild-type genomic constellation 
by FISH (Table 1). According to these observations, a cutoff 
value of 0.4 was considered a relevant threshold for qRT-PCR 
rather than the mathematical cutoff value of 0.3 originally 
applied. Of 154 qRT-PCR–negative tumors with interpretable 
FISH, 152 were confirmed negative by FISH, whereas two 
cases with an unbalanced, yet low expression of the 3´ portion 
(# 20: 0.22; # 21: 0.15) were found positive on FISH. The six 
tumors with expression of the full-length transcript were all 
negative for genomic ALK rearrangements (Fig. 2). In four of 
them, additional ALK gene copies (3–4 gene copies, occasion-
ally polysomic nuclei) were detected in more than 25% of the 
tumor cells. A comparable genomic constellation, however, 
was observed in about one third of the 152 FISH-negative 
cases without detectable expression of ALK. Our qRT-PCR 
assay, thus, accurately typed 97% (177 of 182) of tumors ana-
lyzed by FISH in parallel and strongly suggested rearrange-
ments of ALK in three tumors with insufficient or ambiguous 
FISH analysis (data not shown). In addition, qRT-PCR was 
able to identify cases with full-length ALK overexpression not 
detectable by FISH.
Influence of Sample Size and Tumor 
Cell Content on ALK Expression
Positive qRT-PCR results were obtained for resection 
specimens and for bronchoscopic biopsies, with the smallest 
specimens being 0.1 cm2 in size (Table 1). The relative expres-
sion of the 3´ ALK portion was independent of the sample 
size. The tumor cell content of cases with significant ALK 
transcript expression ranged from 10% to 90%. Although 
high expression values (3´ portion expression >1.0) were 
only observed in samples with a tumor cell content of more 
than 50%, the expression did not strictly correlate with tumor 
content (Pearson’s correlation, p= 0.21), and ALK mRNA was 
reliably detectable in four cases with 10% to 30% tumor cells 
(expression values 0.49–0.86).
ALK Protein Expression in ALK-Rearranged 
versus ALK–Wild-Type Tumors
ALK protein expression was assessed in 250 samples 
by immunostaining. The D5F3 antibody detected ALK protein 
overexpression in all 21 samples harboring an ALK rearrange-
ment verified by FISH (Table 1, Fig. 2). Four ALK-rearranged 
adenocarcinomas showed strong staining of the tumor cells 
for the protein, and another 10 cases were moderately posi-
tive. Seven cases altogether showed weak and often focal 
staining. Expression levels of the 3´ portion of the ALK tran-
script did not necessarily correlate with the intensity of the 
immunohistochemical staining (Pearson’s correlation, p= 
0.20; Supplementary Figure 2 [Supplemental Digital Content 
3, http://links.lww.com/JTO/A513]). Of five samples with 
 up-regulated full-length transcription analyzed, weak ALK 
protein expression was detected in four samples (#22, #23, 
#25, #27), whereas ALK protein was not detectable in one case 
(#24) (Table 1, Fig. 2). Of importance, 224 ALK  wild-type 
tumors showed no staining with the ALK antibody.
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Mutation Analysis of the Kinase Region
In neuroblastoma, expression of full-length ALK tran-
scripts is frequently associated with mutations in the kinase 
domain.19 Therefore, we examined this region (exons 20–29) 
for mutations in all six cases with full-length ALK expres-
sion. In case #25, a heterozygous nucleotide substitution was 
detected (3659C>A), which results in the substitution of ser-
ine by tyrosine within the central part of the kinase domain 
(S1220Y) (Fig. 3). This nucleotide change was also present in 
DNA extracted from tumor-free lung tissue from the patient, 
and was thus of germline origin; the expression of ALK tran-
scripts, however, was restricted to tumor cells (Fig. 3).
Clinico-Pathological Characteristics 
of ALK-Positive Lung Cancers
Patients with ALK rearrangements had a median age 
of 59 years; about half of them (48%) were 60 years old or 
younger. Two patients were aged 75 years or older. The majority 
of patients with ALK-rearranged tumors were women (74%). 
We did not observe any prevalence of the ALK translocation 
in nonsmoking versus smoking women (8 versus 7 patients; 
Table 1), whereas four of five male patients with proven ALK 
translocation had been nonsmokers. In contrast, three of six 
patients with tumors expressing the full-length transcript were 
male smokers. The median age of patients with ALK-expressing 
tumors was 59 years (range, 42–82) (Table 1).
In our series, ALK rearrangement did not correlate with 
tumor grading nor with TNM status. ALK translocations were 
not restricted to advanced cancers, but were also detected 
in pT1 and low-grade tumors (Table 1). The presence of a 
 signet-ring cell component was observed in roughly one third 
of ALK-rearranged and ALK-expressing tumors (39% and 
33%, respectively). There was no clear prevalence of a spe-
cific histological subtype among ALK-positive tumors. 34% 
were classified as predominantly solid and 31% as glandu-
lar adenocarcinomas; 24% had a mucinous differentiation 
(Table 1). None of the 22 ALK-rearranged or full-length ALK–
expressing tumors analyzed harbored coexisting EGFR muta-
tions (data not shown).
DISCUSSION
Rearrangement of ALK results in the expression of the 
3´ part of the gene fused with EML4 or alternative partners, 
whereas the ALK 5´ portion remains unexpressed. Taking 
advantage of this feature, we have developed a diagnostic test 
that reliably detects ALK rearrangement in FFPE tissues by 
means of recognizing an unbalanced ALK transcript expres-
sion independent of the fusion partner. Most notably, the assay 
also provides information about the expression of intact ALK 
transcripts. Recent reports have shown the principal poten-
tial of such an approach. All these approaches, however, are 
of limited utility in routine diagnostics using FFPE material. 
The qRT-PCR assay developed by Wang and colleagues12 
detected rearrangements in frozen tissue samples with excel-
lent sensitivity, but had not been adapted to FFPE specimens. 
Two alternative technologies based on exon array analyses or 
FIGURE 2.  Comparative analysis of ALK 
by qRT-PCR measuring the expression of 
the 5' and the 3' portion of ALK transcripts 
(left), FISH using probes flanking the ALK 
gene (middle) and immunostaining for ALK 
protein (right). A and B, ALK-rearranged 
tumors expressing the ALK 3' portion; (C) 
tumor expressing full-length ALK transcript 
in the absence of gene rearrangement. 
Gray bars, ALK transcript 5'portion; dark 
gray bars, ALK transcript 3' portion; arrows, 
split FISH signals characteristic of an ALK 
rearrangement; scale bar, 200 μm. ALK, 
anaplastic large-cell lymphoma kinase; 
qRT-PCR, quantitative reverse transcription 
polymerase chain reaction; NSCLC, non–
small-cell lung cancer; FISH, fluorescence in 
situ hybridization.
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NanoString’s nCounter technology were highly sensitive for 
the detection of ALK fusion transcripts, but are not readily 
available in most pathology laboratories.13,14 In contrast, our 
approach is based on the qRT-PCR technique that is well-
established in many routine laboratories. To cope with the 
poor quality of RNA isolated from routine FFPE specimens 
we took advantage of (1) an RNA isolation method that was 
optimized to reverse formaldehyde modification and (2) small 
RT-PCR amplicons to allow for the use of fragmented nucleic 
acids for efficient amplification of ALK cDNA.
When applied to a large series of 652 routine NSCLC 
specimens, the qRT-PCR assay was interpretable in 80% of 
cases, which is about the range reported for ALK breakapart 
FISH (60%–90%20,21; 92% in this study), and showed a high 
sensitivity and specificity for the detection of ALK rearrange-
ments. Compared with FISH, the qRT-PCR accurately typed 
97% of the tumors (19 ALK-rearranged and 158 nonrear-
ranged cases) and also strongly suggested rearrangements 
in three tumors with insufficient or ambiguous FISH results. 
Three tumors with low qRT-PCR expression (between 0.3 and 
0.4) were negative by FISH and IHC. The risk of providing 
false-positive results would thus be minimized by selecting a 
cutoff value of 0.4. However, in two FISH-positive cases an 
unbalanced expression of the 3´ portion of ALK was noted, 
which, however, was below the cutoff level. The number of 
tumor cells (40%–50%) in those cases, obviously, was not a 
limiting factor, because unbalanced ALK expression was reli-
ably detected in four specimens with as few as 10% to 30% 
tumor cells. The low expression encountered might rather 
be caused by a non–EML4-ALK rearrangement as reported 
in one case that was positive by FISH and IHC but negative 
by RT-PCR.20 Whether a low number of fusion transcripts 
impedes treatment with ALK kinase inhibitors and whether, 
consequently, its quantification should be part of the diagnos-
tic procedure, warrants further investigation.
Currently, FISH using breakapart probes is the gold 
standard technique for the diagnosis of ALK rearrangements 
in lung adenocarcinomas. FISH, however, is a  low-throughput 
approach that requires specialized technical equipment and 
expertise, especially with respect to the complex signal con-
stellation arising from intrachromosomal inversions com-
bined with deletions in the setting of polysomy typical of lung 
cancer. qRT-PCR, in contrast, is an inexpensive and rapid 
technique with easy-to-use protocols. By using a 96-well 
or 384-well detection system this assay becomes relatively 
 high-throughput, which makes the rapid screening of larger 
patient cohorts efficient. In addition, small biopsy fragments 
with low tumor cell content will suffice for the diagnosis: 
ALK expression was reliably detected in resection specimens 
and in small biopsies with as few as 10% to 30% tumor cells. 
Furthermore, using the extraction method used here, it will 
be possible to isolate simultaneously both RNA and DNA 
from the same specimens, which opens up the possibility of 
combining PCR-based molecular testing with DNA mutation 
analysis and optimizing tissue processing.
Several authors have recommended IHC testing as a 
prescreening tool.7,21,22 In our study, ALK protein expression 
was restricted to tumors that harbored ALK rearrangements or 
overexpressed full-length ALK. This raises the possibility of 
diagnosing ALK-positive tumors using routine IHC. However, 
several limitations of the IHC approach have to be considered, 
such as: (1) Tissue staining for ALK is often weak and focal 
(in this study in one third of rearranged cases), which requires 
confirmatory FISH or RT-PCR; (2) Although not observed 
in this study, false-negative results have been reported for 
 ALK-rearranged cases using IHC23; and (3) the use of ALK 
FIGURE 3. ALK mutation and full-length transcript 
expression in NSCLC #25. A, Tumor and nonma-
lignant cells harbor the heterozygous nucleotide 
substitution 3659C>A, resulting in the replacement 
of a serine by a tyrosine within the kinase domain 
(S1220Y). B, Full-length ALK transcript was expressed 
in tumor, but not in nonmalignant cells, as detected 
by qRT-PCR. Light gray bars, ALK 5'portion; dark 
gray bars, ALK 3' portion. ALK, anaplastic large-cell 
lymphoma kinase; qRT-PCR, quantitative reverse 
transcription polymerase chain reaction; NSCLC, 
non–small-cell lung cancer. 
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antibodies raised against the C-terminal portion of the protein 
cannot discriminate between the expression of a fusion protein 
or the full-length ALK protein. This, again, requires ALK pro-
tein expressing cases to be re-examined by qRT-PCR (or FISH).
In lung adenocarcinoma, ALK is generally activated 
by the expression of chimeric proteins containing the ALK 
kinase domain, whereas in other ALK-positive neoplasms 
(e.g., neuroblastoma, sarcoma) ALK activation is caused by 
overexpression of wild-type or mutated transcripts (see ref. 
24 for review). Only recently, oncogenic point mutations of 
ALK have been detected in lung cancer.25–27 In our series of 
NSCLC,  up-regulated expression of nonrearranged tran-
scripts was observed in six cases altogether (1.1%). In four of 
five tumors analyzed, up-regulated transcription was associ-
ated with detectable amounts of ALK protein. In one of those 
cases, an amino acid substitution within the kinase domain 
(S1220Y) was identified. The replacement of a serine by a 
tyrosine residue might interfere with the kinase activity and 
with the binding of a kinase inhibitor as demonstrated for 
other mutations in this region.26,28,29 Although this mutation 
was of germline origin, its expression was restricted to tumor 
cells. To date, this nucleotide exchange has not been reported 
(http://www.ncbi.nlm.nih.gov/SNP/), which argues against a 
polymorphic character but rather points to a genetic predis-
position for NSCLC comparable with familial and sporadic 
cases of neuroblastoma carrying ALK germline mutations.30,31 
In our study, DNA sequence analysis focused on the kinase 
domain, because the majority of activating mutations in neu-
roblastoma affects this region.32 Oncogenic ALK mutations 
detected in lung cancer, however, are distributed in different 
protein domains.25–27 Thus, it is possible that mutations exist 
outside the kinase domain in the five other cases expressing 
full-length ALK.
Three lines of evidence indicate that the identification 
of up-regulated full-length ALK transcripts in lung adenocar-
cinoma might be of therapeutic relevance: (1) Several ALK 
inhibitors (crizotinib, CEP-14083, TAE684, CH5424802) 
inhibit the growth of neuroblastoma cells overexpressing 
wild-type or mutated full-length ALK in vitro and in xenograft 
models.33–36 Crizotinib is currently being tested for the treat-
ment of neuroblastoma (NCT00939770, ClinicalTrials.gov); 
(2) Ectopic overexpression of wild-type or mutated full-length 
ALK confers a tumorigenic phenotype to NSCLC cells and 
xenograft tumors, and treatment with different ALK inhibi-
tors (WHI-P154, NVP-TAE684) resulted in the regression of 
tumors and suppression of metastasis26; (3) Several reports 
describe NSCLC tumors that were IHC positive but FISH neg-
ative,7,9,37–41 which is indicative of up-regulated ALK expres-
sion without gene rearrangement. Of pivotal interest, one of 
those patients was treated with crizotinib and showed a dra-
matic therapy response.40 To what extent treatment response 
of lung adenocarcinomas expressing full-length ALK might be 
dependent on certain mutations or requires a critical threshold 
of expression (as shown for neuroblastoma)34 will have to be 
determined in future studies.
The clinical and structural features of the  ALK-rearranged 
cases in our series confirms previous observations that ALK 
rearrangement tends to be associated with younger age, female 
sex, and the presence of a signet-ring cell component.9,10,20,22,42 
Preanalytical selection of patients using these parameters, 
however, would have missed as many as 74% of patients with 
detectable ALK rearrangements, which underlines the necessity 
for molecular screening. In contrast to other reports,10,13,22,43 an 
association with advanced disease or smoking behavior of the 
predominantly female patients was not observed in our series. 
Thus, our observations are well in line with the proposed guide-
lines for the selection of lung cancer patients for ALK tyrosine 
kinase inhibitors, which recommends molecular ALK testing in 
all patients with advanced-stage adenocarcinoma, regardless of 
age, sex, or smoking history.44 Most notably, full-length ALK 
expression was preferentially found in male patients, most of 
them smokers.
In conclusion, the qRT-PCR approach presented here 
reliably detects ALK-rearranged tumors independently of 
the fusion partner and also identifies cases with full-length 
transcript expression of the gene not detectable by FISH. 
Thus, qRT-PCR seems to be a sensitive, easy-to-perform, and 
high-throughput technique suitable for the routine diagnosis 
of ALK activation not only in lung cancer, but also in other 
tumor entities where rearrangements with alternative fusion 
partners (t(2;5)+ anaplastic large-cell lymphoma, ALK+ dif-
fuse large B-cell lymphoma, ALK+ inflammatory myofi-
broblastic tumors), or transcriptional up-regulation of ALK 
(neuroblastoma, sarcomas) are prevalent.
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